Green Cross Medical Science Corporation (142280) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Green Cross Medical Science Corporation stock KRW 2,440, price KRW 2,800, that is 12.9% below the price, quality 52 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2,395 KRW – 12,900 KRW · fair‑value band 1,754 KRW – 3,178 KRW · the 2,800 KRW price screens above the 2,440 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Green Cross Medical Science in your weekly email
Every Wednesday you see whether Green Cross Medical Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally.
Show moreShow less
The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases.
It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol.
The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and " GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo.
Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis.
The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.
Stock analysis
Green Cross Medical Science Corporation (142280) currently trades at 2,800 KRW, while our model-based Fair Value estimate is 2,440 KRW, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 2,983 KRW per share, and 5 of the 23 models we run sit above the 2,800 KRW price.
Bear case: the Earnings-Based group reads lowest at 905.53 KRW, and 18 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1,754 KRW (bear) to 3,178 KRW (bull), the price of 2,800 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Green Cross Medical Science Corporation reported revenue of 108B KRW in FY2025 versus 102B KRW in FY2021, a compound +1.6%/yr. Reported net income was 3.7B KRW in FY2025.
Key figures
Market cap 67.2B KRW (≈ $49.7M) Micro · P/S ratio 0.80 · EPS (TTM) −90.22 KRW · Net margin −2.1% · Return on equity −4.0% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin 2.7% · Revenue (TTM) 102B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −13%, 142280 screens cheaper than that median.
Fair Value models
Bear1,754 KRWFair Value 2,440 KRWBull3,178 KRW
Price 2,800 KRW · Downside -12.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Start year 2020 (pandemic). Over 10 years: +2.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
⚠ Revenue per share shrinking 7.0%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +21.5% a year for the price.
Compare Green Cross Medical Science Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−12.9% · Above median
Profitability
Return on assets4.1% · Below median
Net margin (12 months)−2.1% · Bottom 25%
Operating margin (12 months)2.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)−10.9% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.51× · Cheaper than median
P/S (12 months)0.66× · Cheapest 25%
Price / free cash flow (fiscal year)29.3× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Green Cross Medical Science Corporation Fair Value". https://www.fairvalue-calculator.com/stock/142280
Frequently asked questions
Is Green Cross Medical Science Corporation (142280) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,440 KRW versus a price of 2,800 KRW, about 13% lower (overvalued).
What is the fair value of 142280?
Our model-based fair value for Green Cross Medical Science Corporation is 2,440 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 2,800 KRW.
What is the quality score of 142280?
Green Cross Medical Science Corporation has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Green Cross Medical Science Corporation (142280)?
Our model-based price target is the fair value of 2,440 KRW (as of Nov 9, 2026) from 23 valuation models. Cautious scenario 1,754 KRW, optimistic scenario 3,178 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Green Cross Medical Science Corporation stock forecast for 2026?
Our models put fair value at 2,440 KRW, about 13% lower versus a price of 2,800 KRW (overvalued). Cautious scenario 1,754 KRW, optimistic scenario 3,178 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Green Cross Medical Science Corporation (142280)?
Green Cross Medical Science Corporation reported trailing-twelve-month revenue of about 102B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into Green Cross Medical Science Corporation (142280)?
For today's price to be fair in a discounted-cash-flow model, Green Cross Medical Science Corporation would have to grow free cash flow by +24.0 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.9 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 142280 use?
Our models discount Green Cross Medical Science Corporation at 12.2 %: a base by market capitalisation (micro), damped by beta 0.71, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Green Cross Medical Science Corporation that is +24.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Green Cross Medical Science Corporation (142280) delivered so far?
Over the past 5 years revenue at Green Cross Medical Science Corporation grew -0.9 % a year. The price currently implies free-cash-flow growth of +24.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Green Cross Medical Science Corporation (142280) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Green Cross Medical Science Corporation (+24.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Green Cross Medical Science Corporation (142280)?
The free-cash-flow yield on the price is 3.77 %: that much free cash flow Green Cross Medical Science Corporation produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Green Cross Medical Science Corporation (142280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Green Cross Medical Science Corporation it is 2,440 KRW per share (as of Nov 9, 2026), against a price of 2,800 KRW. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Green Cross Medical Science Corporation stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 142280 trades above its calculated fair value: price 2,800 KRW, fair value 2,440 KRW, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 142280?
No. The price is what the market pays today (2,800 KRW); the fair value is what the company's own numbers justify (2,440 KRW). For Green Cross Medical Science Corporation the two are 360.27 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Green Cross Medical Science Corporation worth?
The market values Green Cross Medical Science Corporation at about 67.2B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 2,800 KRW; our models calculate a fair value of 2,440 KRW per share.
What do the bullish and bearish scenarios say about 142280?
Our models span a range for Green Cross Medical Science Corporation: cautious scenario 1,754 KRW, base 2,440 KRW, optimistic 3,178 KRW per share (as of Nov 9, 2026, price 2,800 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Green Cross Medical Science Corporation (142280)?
Balance-sheet figures for Green Cross Medical Science Corporation (as of Nov 9, 2026): return on equity −4.0%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 142280 from its 52-week high?
Green Cross Medical Science Corporation trades at 2,800 KRW, about 55% below its 52-week high of 6,230 KRW and 17% above the low of 2,395 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,440 KRW is for.
Which stocks are comparable to Green Cross Medical Science Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Green Cross Medical Science Corporation stock attractive at the current price?
The data as of Nov 9, 2026: price 2,800 KRW, calculated fair value 2,440 KRW (−13%), Quality Score 52/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 142280 calculated?
We run Green Cross Medical Science Corporation through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,440 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Green Cross Medical Science Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Green Cross Medical Science Corporation (142280)?
The closing price on Nov 6, 2026 was 2,800 KRW. Our model-based fair value is 2,440 KRW, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Green Cross Medical Science Corporation right now?
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1,754 KRW to 3,178 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Green Cross Medical Science Corporation
How large is the market capitalisation of Green Cross Medical Science Corporation (142280)?
The market capitalisation of Green Cross Medical Science Corporation is 67.2B KRW (≈ $49.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Green Cross Medical Science Corporation (142280)?
The price-to-sales ratio of Green Cross Medical Science Corporation is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Green Cross Medical Science Corporation (142280)?
Earnings per share at Green Cross Medical Science Corporation are −90.22 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Green Cross Medical Science Corporation (142280)?
The net margin of Green Cross Medical Science Corporation is −2.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Green Cross Medical Science Corporation (142280)?
The return on equity (ROE) of Green Cross Medical Science Corporation is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Green Cross Medical Science Corporation (142280)?
On an EBIT basis the return on assets of Green Cross Medical Science Corporation is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Green Cross Medical Science Corporation (142280)?
The operating margin of Green Cross Medical Science Corporation is 2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Green Cross Medical Science Corporation (142280)?
Revenue at Green Cross Medical Science Corporation is growing −10.9% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Green Cross Medical Science Corporation (142280)?
Earnings per share at Green Cross Medical Science Corporation are growing +41.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Green Cross Medical Science Corporation (142280) carry?
The net debt of Green Cross Medical Science Corporation is 10.2B KRW (fiscal year 2025, ≈ 4.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Green Cross Medical Science Corporation in the live analysis
One click puts Green Cross Medical Science Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026